Biopharmaceutics Drug Disposition Classification System (BDDCS) and Its Application in Drug Discovery and Development
|
|
- Dina Harvey
- 5 years ago
- Views:
Transcription
1 Biopharmaceutics Drug Disposition Classification System (BDDCS) and Its Application in Drug Discovery and Development Leslie Z. Benet, Ph.D. Professor of Bioengineering and Therapeutic Sciences University of California San Francisco AAPS Physical Pharmacy and Biopharmaceutics Section Webinar September 6, 2012
2 Cellular and animal studies from our laboratory between examining transporter-enzyme interplay led us to make 22 predictions concerning drug absorption and disposition. These predictions served as the basis for the BDDCS as described in our January 2005 Pharmaceutical Research paper C-Y. Wu and L.Z. Benet. Pharm. Res. 22:11-23 (2005)
3 Wu and Benet recognized that for drugs exhibiting high intestinal permeability rates the major route of elimination in humans was via metabolism, while drugs exhibiting poor intestinal permeability rates were primarily eliminated in humans as unchanged drug in the urine and bile. Therefore they suggested that at least for drugs on the market, where extent of metabolism is always known, but extent of absorption may not have been quantitated, that metabolism may serve as a surrogate for permeability rate.
4 Low Permeability Rate High Permeability Rate Major Routes of Drug Elimination High Solubility Class 1 Metabolism Low Solubility Class 2 Metabolism Class 3 Renal & Biliary Elimination of Unchanged Drug Class 4 Renal & Biliary Elimination of Unchanged Drug
5 Biopharmaceutics Drug Disposition Classification System Extensive Metabolism Poor Metabolism BDDCS High Solubility Class 1 High Solubility Extensive Metabolism (Rapid Dissolution and 70% Metabolism for Biowaiver) Low Solubility Class 2 Low Solubility Extensive Metabolism Class 3 High Solubility Poor Metabolism Class 4 Low Solubility Poor Metabolism Wu and Benet, Pharm. Res. 22: (2005)
6 Major Differences Between BDDCS and BCS Purpose: BCS Facilitate biowaivers of in vivo bioequivalence studies. BDDCS Prediction of drug disposition and potential DDIs in the intestine & liver. Criterion: BDDCS Predictions based on intestinal permeability rate BCS Biowaivers are based on extent of intestinal absorption (permeability), which in a number of cases does not correlate with jejunal permeability rates
7 It should be noted that for such simple four class categorizations, high permeability does a remarkable job in predicting both extensive absorption (BCS) and extensive metabolism (BDDCS). However, low permeability is better at predicting poor metabolism than in predicting poor absorption for a number of Class 3 and 4 drugs
8 The recognition of the correlation between intestinal permeability rate and extent of metabolism allows prediction of BDDCS class for an NME to be based on passive membrane permeability. Our recent work suggests that even measurements in nonviable membranes like PAMPA will give the correct prediction Evaluating the Link between Passive Transcellular Permeability and Extent of Drug Absorption and Metabolism in Humans. C.A. Larregieu and L.Z. Benet, AAPS Abstract, October 2011
9 The recognition of the correlation between intestinal permeability rate and extent of metabolism and our finding that a nonviable membrane can serve as surrogate marker preceded an explanation for these findings. We suspect that high permeability rate compounds are readily reabsorbed from the kidney lumen and from the bile facilitating multiple access to the metabolic enzymes. This would be particularly important for metabolically eliminated drugs with low hepatic clearance (e.g., diazepam).
10 The Use of BDDCS for Drugs on the Market Predict potential drug-drug interactions not tested in the drug approval process Predict the potential relevance of transporterenzyme interplay Assist the prediction of when and when not transporter and/or enzyme pharmacogenetic variants may be clinically relevant Predict when transporter inhibition of uremic toxins may change hepatic elimination Predict the brain disposition Increase the eligibility of drugs for BCS Class 1 biowaivers using measures of metabolism
11 Low Permeability/ Metabolism High Permeability/ Metabolism Oral Dosing Transporter Effects High Solubility Class 1 Transporter effects minimal in gut and liver Class 3 Absorptive transporter effects predominate (but can be modulated by efflux transporters) Low Solubility Class 2 Efflux transporter effects predominate in gut, but both uptake & efflux transporters can affect liver Class 4 Absorptive and efflux transporter effects could be important
12 Low Permeability/ Metabolism High Permeability/ Metabolism Oral Dosing Transporter Effects High Solubility Class 1 Transporter effects minimal in gut and liver Class 3 Absorptive transporter effects predominate (but can be modulated by efflux transporters) Low Solubility Class 2 Efflux transporter effects predominate in gut, but both uptake & efflux transporters can affect liver Class 4 Absorptive and efflux transporter effects could be important
13 Class 1 highly soluble, high permeability, extensively metabolized drugs Transporter effects will be minimal in the intestine and the liver Even compounds like verapamil that can be shown in certain cellular systems (MDR1-MDCK) to be a substrate of P-gp will exhibit no clinically significant P-gp substrate effects in the gut and liver
14 Class 1 Drugs A major proposition of BDDCS is that Class 1 drugs are not substrates of clinical relevance for transporters in the intestine and liver (but the BBB and the kidney are not the gut and liver) [pre 2011 limitation]
15 Low Permeability High Permeability Intestinal: Transporter Effects High Solubility Class 1 Transporter effects minimal Class 3 Absorptive transporter effects predominate (but can be modulated by efflux transporters) Low Solubility Class 2 Efflux transporter effects predominate Class 4 Absorptive and efflux transporter effects could be important
16 Efflux transporter effects will predominate for Class 2 compounds. The high permeability of these compounds will allow ready access into the gut membranes, but the low solubility will limit the concentrations coming into the enterocytes, thereby preventing saturation of the efflux transporters.
17 Transporter-enzyme interplay will be primarily important for Class 2 compounds that are substrates for CYP 3A and Phase 2 gut enzymes (e.g. glucuronosyltransferases) where efflux transporter effects can control the access of the drug to the gut enzymes. DDIs in the intestine can lead to changes in metabolism that result from efflux transporter inhibition.
18 Recent Transporter Interplay Reviews from the Benet Lab The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs. S. Shugarts and L. Z. Benet. Pharm. Res. 26, (2009). The Drug Transporter-Metabolism Alliance: Uncovering and Defining the Interplay. L. Z. Benet. Mol. Pharmaceut. 6, (2009). Predicting Drug Disposition via Application of a Biopharmaceutics Drug Disposition Classification System. L. Z. Benet. Basic Clin. Pharmacol. Toxicol. 106, (2010).
19 Low Permeability/ Metabolism High Permeability/ Metabolism Oral Dosing Transporter Effects High Solubility Class 1 Transporter effects minimal in gut and liver Class 3 Absorptive transporter effects predominate (but can be modulated by efflux transporters) Low Solubility Class 2 Efflux transporter effects predominate in gut, but both uptake & efflux transporters can affect liver Class 4 Absorptive and efflux transporter effects could be important
20 Class 2 poorly soluble, highly permeable, extensively metabolized drugs Efflux transporter effects will be important in the intestine and the liver In the intestine efflux transporter enzyme (CYP 3A4 and UGTs) interplay can markedly affect oral bioavailability In the liver the efflux transporter-enzyme interplay will yield counteractive effects to that seen in the intestine. Uptake transporters can be important for the liver but not the intestine.
21 Class 2 poorly soluble, highly permeable, extensively metabolized drugs ---DDIs are seen as changes in metabolism Efflux transporter effects will be important in the intestine and the liver Metabolism changes due to transporter DDIs In the intestine efflux transporter enzyme (CYP 3A4 and UGTs) interplay can markedly affect oral bioavailability The overlap of inhibitors for gut enzymes and gut efflux transporters can cause multiple DDI causation. In the liver the efflux transporter-enzyme interplay will yield counteractive effects to that seen in the intestine --- Inhibition of efflux transporters causes decreased metabolism in the intestine and increased metabolism in the liver. Uptake transporters can be important for the liver but not the intestine --- Inhibition of uptake transporters causes decreased metabolism in the liver
22 Elucidating Rifampin s Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effect of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite HongXia Zheng, Yong Huang, Lynda Frassetto, and Leslie Z. Benet Clinical Pharmacology & Therapeutics 85:78-85 (2009)
23 Study Design Effects of Single IV Rifampin (RIF) on Glyburide Ten Healthy Volunteers Visit 1 Day 1 Glyburide 1.25mg P.O. (PK Study) Visit 2 Day 8 Rifampin 600mg I.V. Glyburide 1.25mg P.O. (PK Study)
24 Study Design (Continued) Inhibition and Induction Effects of RIF on Glyburide ALL Healthy Volunteers Rifampin 600mg P.O. for 6 days Visit 3 Day 15 Rifampin 600mg I.V. Glyburide 1.25mg P.O. (PK study) Visit 4 Day 17 Glyburide 1.25mg P.O. (PK study)
25 Glyburide (ng/ml) Inhibition of Glyburide Uptake by IV RIF Glyburide Control RIF IV+Glyburide Time (h) Cmax 81% T1/2 31% * * AUC0-inf 125% CL/F 53% * * Vss/F 60% * P<0.05 *
26 Glyburide (ng/ml) CYP450 Induction Effect on Glyburide When No RIF Present in the Plasma Glyburide Control Glyburide After RIF Induction Time (h) * * 197% * Cmax 48% AUC0-inf 63% CL/F Vss/F 32% ns
27 Glyburide (ng/ml) Uptake Inhibition and CYP450 Induction Effects on Glyburide When RIF Present in the Plasma 600 Glyburide Control RIF IV+Glyburide After RIF Induction Time (h) * * Cmax 9% AUC0-inf 22% CL/F 37% Vss/F 43% *
28 Low Permeability/ Metabolism High Permeability/ Metabolism Oral Dosing Transporter Effects High Solubility Class 1 Transporter effects minimal in gut and liver Class 3 Absorptive transporter effects predominate (but can be modulated by efflux transporters) Low Solubility Class 2 Efflux transporter effects predominate in gut, but both uptake & efflux transporters can affect liver Class 4 Absorptive and efflux transporter effects could be important
29 Class 3 highly soluble, low permeability, poorly metabolized drugs Uptake transporters will be important for intestinal absorption and liver entry for these poor permeability drugs However, once these poorly permeable drugs get into the enterocyte or the hepatocyte efflux transporter effects can occur.
30 Class 3 highly soluble, low permeability, poorly metabolized drugs Uptake transporters will be important for intestinal absorption and liver entry for these poor permeability drugs However, once these poorly permeable drugs get into the enterocyte or the hepatocyte efflux transporter effects can occur. DDIs will be transporter mediated and cause changes in biliary and renal excretion for Class 3 and 4 drugs
31 The Use of BDDCS for Drugs on the Market Predict potential drug-drug interactions not tested in the drug approval process Predict the potential relevance of transporter-enzyme interplay Assist the prediction of when and when not transporter and/or enzyme pharmacogenetic variants may be clinically relevant Predict when transporter inhibition of uremic toxins may change hepatic elimination Predict the brain disposition Increase the eligibility of drugs for BCS Class 1 biowaivers using measures of metabolism
32 Recently the FDA has recommended that studies in renal failure patients be carried out even for drugs where renal elimination of unchanged drug is minimal This recommendation comes about in part based on a finding that was related to the development and characterization of BDDCS
33 Studies of Drugs Primarily Eliminated by Metabolism in Renal Failure Patients Potential inhibition or downregulation of metabolic enzymes by uremic toxins could be tested in vitro. We began to recognize that previously unexplained effects of renal disease on hepatic metabolism can result from accumulation of substances (toxins) in renal failure that modify hepatic uptake and efflux transporters. Sun et al., Effect of Uremic Toxins on Hepatic Uptake and Metabolism of Erythromycin. Drug Metab. Dispos. 32: (2004). Sun et al., Hepatic Clearance, But Not Gut Availability, of Erythromycin is Altered in Patients with End-Stage Renal Disease. Clin. Pharmacol. Ther. 87: (2010)
34 Hepatic Clearance, but Not Gut Availability of Erythromycin Is Altered in Patients with End-Stage Renal Disease Hong Sun, Lynda A. Frassetto, Yong Huang and Leslie Z. Benet Clinical Pharmacology & Therapeutics 87: (2010) Erythromycin is a Class 3 drug that is primarily eliminated unchanged in the bile. It is a substrate for hepatic uptake transporters that we have shown can be inhibited by uremic toxins in end-stage renal disease patients.
35 Erythromycin PK Parameters (mean ± SD) in 12 ESRD patients and12 controls after 125 mg iv and 250 mg oral doses Parameter Healthy Controls ESRD Patients % Change (p value) CL H (L/h/kg) 0.51 ± ± % (p = 0.01) F % 15 ± 6 21 ± 7 36% (NS, p = 0.36) F H % 50 ± ± 15 28% (p = 0.015) F abs F G % 33 ± ± 28
36 Potential DDIs Predicted by BDDCS Class 1: Only metabolic in the intestine and liver Class 2: Metabolic, efflux transporter and efflux transporter-enzyme interplay in the intestine. Metabolic, uptake transporter, efflux transporter and transporter-enzyme interplay in the liver. Class 3 and 4: Uptake transporter, efflux transporter and uptake-efflux transporter interplay
37 Caution A simple 4 category system won t predict every interaction. BDDCS doesn t propose that every drug in the class will be substrates or not substrates for uptake and efflux transporters. Rather, BDDCS enumerates what interactions should and should not be investigated.
38 The Use of BDDCS for Drugs on the Market Predict potential drug-drug interactions not tested in the drug approval process Predict the potential relevance of transporter-enzyme interplay Assist the prediction of when and when not transporter and/or enzyme pharmacogenetic variants may be clinically relevant Predict when transporter inhibition of uremic toxins may change hepatic elimination Predict the brain disposition Increase the eligibility of drugs for BCS Class 1 biowaivers using measures of metabolism
39 Since extent of metabolism correctly predicts high vs low intestinal permeability for at least 33 of 35 drugs, where human permeability measurements exist, Benet and co-workers a propose the following: We recommend that regulatory agencies add the extent of drug metabolism (i.e., 90% metabolized) as an alternate method for the extent of drug absorption (i.e., 90% absorbed) in defining Class 1 drugs suitable for a waiver of in vivo studies of bioequivalence. a Benet, Amidon, Barends, Lennernäs, Polli, Shah, Stavchansky & Yu. The Use of BDDCS in Classifying the Permeability of Marketed Drugs, Pharm. Res., 25: (2008)
40 A major advantage of BDDCS is that for drugs on the market, we know the extent of metabolism and they can generally be correctly classified without expensive and time consuming human permeability studies. I am very pleased that the January 2010 EMA Guideline on the Investigation of Bioequivalence includes metabolism as a criteria for permeability and that EMA only accepts extent of absorption as a criteria for Class 1 biowaivers. Also, the FDA has said informally that they would accept metabolism information as a basis for biowaivers.
41 Additional Uses of BDDCS for New Molecular Entities and Its Role in Drug Development Predict the major route of elimination for an NME in humans (metabolisms vs excretion of unchanged drug in the urine and bile) Predict the relevance of transporters and transporter-enzyme interplay in drug disposition as described earlier for drugs on the market Predict central or lack of central effects Predict the effects of high fat meals on the extent of bioavailability
42 How can the concepts presented be used in predicting DMPK of an NME? In silico methodology, at present, is not sufficient (except possibly for V ss ). We cannot predict clearance & bioavailability Permeability measures in Caco-2, MDCK or PAMPA vs metoprolol or labetalol will predict Class 1 & 2 vs. 3 & 4 and thus major route of elimination in humans. Is solubility over the ph range more than 0.2 mg/ml ( i.e., 50 mg highest dose strength) as proposed by Pfizer scientists, defining Class 1 & 3 vs. 2 & 4?
43 Can in silico models predict BDDCS class? BDDCS Applied to Over 900 Drugs Leslie Z. Benet, Fabio Broccatelli, and Tudor I. Oprea AAPS Journal 13: (2011)
44 Here we compile the BDDCS classification for 927 drugs, which include 30 active metabolites. Of the 897 parent drugs, 78.8% (707) are administered orally. Where the lowest measured solubility is found this value is reported for 72.7% (513) of these orally administered drugs and a Dose Number is recorded. Measured values are reported for percent excreted unchanged in urine, Log P and Log D7.4 when available. For all 927 compounds, the in silico parameters for predicted Log solubility in water, calculated Log P, Polar Surface Area and the number of hydrogen bond acceptors and hydrogen bond donors for the active moiety are also provided, thereby allowing comparison analyses for both in silico and experimentally measured values. We discuss the potential use of BDDCS to estimate disposition characteristics of novel chemicals (new molecular entities, NMEs) in the early stages of drug discovery and development.
45 High Permeability Low Permeability [LZ Benet, F Broccatelli and TI Oprea, AAPS J. 13: (2011)] [Broccatelli et al., Mol. Pharmaceut. 9: (2012)] Distribution of Drugs on the Market (698 oral IR) vs. Small Molecule NMEs NME percentages from a data set of 28,912 medicinal chemistry compounds tested for at least one target and having affinities at μm or less concentrations. High Solubility Class 1 Marketed Drugs 40% NMEs: 18% Class 3 Marketed Drugs 21% NMEs: 22% Low Solubility Class 2 Marketed Drugs 33% NMEs: 54% Class 4 Marketed Drugs 6% NMEs: 6%
46 Low Permeability High Permeability Best in silico solubility vs measured VolSurf+ r 2 =0.33 (ALOGPS r 2 = 0.24) Distribution of Drugs on the Market (698 oral IR) vs. Small Molecule NMEs [LZ Benet, F Broccatelli and TI Oprea, AAPS J. 13: (2011)] High Solubility Class 1 Marketed Drugs 40% NMEs: 18% 79.3% (55.8%) Class 3 Marketed Drugs 21% NMEs: 22% 90.1% (74.8%) Low Solubility Class 2 Marketed Drugs 33% NMEs: 54% 78.1% (85.1%) Class 4 Marketed Drugs 6% NMEs: 6% 39.5% (82.7%)
47 Low Permeability High Permeability For either measured or calculated Log P >2, the probability of extensive metabolism is 79.9 and 81.0 %, respectively. For Log P values < 0 the probability of poor metabolism is 84.0 % for M Log P and 83.4 % for CLogP. Distribution of Drugs on the Market (698 oral IR) vs. Small Molecule NMEs [LZ Benet, F Broccatelli and TI Oprea, AAPS J. 13: (2011)] High Solubility Class 1 Marketed Drugs 40% NMEs: 18% Class 3 Marketed Drugs 21% NMEs: 22% Low Solubility Class 2 Marketed Drugs 33% NMEs: 54% Class 4 Marketed Drugs 6% NMEs: 6%
48 When Log P values range from 0-2 (31.4% of drugs for M Log P and 27.5% of drugs for CLogP)
49
50 Additional Uses of BDDCS for New Molecular Entities and Its Role in Drug Development Predict the major route of elimination for an NME in humans (metabolisms vs excretion of unchanged drug in the urine and bile) Predict the relevance of transporters and transporterenzyme interplay in drug disposition as described earlier for drugs on the market Predict central or lack of central effects Predict the effects of high fat meals on the extent of bioavailability
51 The Use of BDDCS in Predicting the Brain Disposition of Orally Administered Drugs Fabio Broccatelli, Caroline A. Larregieu, Gabriele Cruciani, Tudor I. Oprea and Leslie Z. Benet Advanced Drug Delivery Reviews 64, (2012)
52 From the literature we were able to identify 153 drugs that met three criteria: a) central or lack of central pharmacodynamic effects were known (BBB+ or BBB-) b) the BDDCS class was identified c) information was available as to whether the drug was or was not a substrate for P-glycoprotein
53 Use of BDDCS in CNS Drug Discovery F. Broccatelli, C. A. Larregieu, G. Cruciani, T. I. Oprea and L. Z. Benet, Advanced Drug Delivery Reviews 64: (2012)
54 Class 1 Drugs A major proposition of BDDCS is that Class 1, P450/UGT metabolized drugs are not substrates of clinical relevance for transporters in the intestine, liver, kidney and brain.
55 Another Implication Class 1 compounds will achieve brain concentrations whether this is desired or not for an NME, which could be the rationale for not always wanting Class 1 NMEs.
56 Low Permeability High Permeability DDI Food Effects (High Fat Meals) Fleisher et al., Clin Pharmacokinet.36(3): , 1999 High Solubility Class 1 F extent T peak Low Solubility Class 2 F extent T peak Class 3 F extent T peak Class 4 F extent T peak
57 The observed effects of high fat meals on the extent of bioavailability, F extent, is consistent with high fat meals inhibiting transporters in the BDDCS predictions. Even if this is not found to be true, the supposition allows predictions of food effects on drug bioavailability. However, many factors are related to food effects, and the predictions here on F are only 70% of the time.
58 The Use of BDDCS for Drugs on the Market Predict potential drug-drug interactions not tested in the drug approval process Predict the potential relevance of transporterenzyme interplay Assist the prediction of when and when not transporter and/or enzyme pharmacogenetic variants may be clinically relevant Predict when transporter inhibition of uremic toxins may change hepatic elimination Predict the brain disposition Increase the eligibility of drugs for BCS Class 1 biowaivers using measures of metabolism
59 Additional Uses of BDDCS for New Molecular Entities and Its Role in Drug Development Predict the major route of elimination for an NME in humans (metabolisms vs excretion of unchanged drug in the urine and bile) Predict the relevance of transporters and transporter-enzyme interplay in drug disposition as described earlier for drugs on the market Predict central or lack of central effects Predict the effects of high fat meals on the extent of bioavailability
60 Collaborators & Acknowledgements Fabio Broccatelli, PhD Gabriele Cruciani, PhD Carolyn Cummins, PhD Joseph Custodio, PhD Margarida Estudante, PhD Lynda Frassetto, MD Adam Frymoyer, MD Yong Huang, PhD Caroline Larregieu, BS Hideaki Okochi, PhD Tudor Oprea, MD, PhD Maribel Reyes, PhD Selma Sahin, PhD Sarah Shugarts, PhD Hong Sun, MD, PhD Chi-Yuan Wu, PhD HongXia Zheng, MD, PhD Funding NIH grants GM and GM for a copy of the slides: Leslie.Benet@ucsf.edu
61 The In Vitro Model that Led to These Hypotheses membrane -P-gp and CYP3A4 in same cell line 6-well plate -Appropriate intestinal model In Vitro Model
62 P app Values for Verapamil in Caco-2 and MDR1-MDCK Cells (Sahin, Custodio, Estudante and Benet, in preparation) Cell Line Concentration PERMEABILITY (nm/s) A-to-B B-to-A Caco-2 10 nm nM+0.5 M GG M M+0.5 M GG MDR1-MDCK 10 nm nM+0.5 M GG M M+0.5 M GG
Biopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application
Biopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application Leslie Z. Benet, Ph.D. Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine
More informationExploiting BDDCS and the Role of Transporters
Exploiting BDDCS and the Role of Transporters (Therapeutic benefit of scientific knowledge of biological transporters, understanding the clinical relevant effects of active transport on oral drug absorption)
More informationLeslie Z. Benet, PhD. Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine University of California San Francisco
Biopharmaceutics Drug Disposition Classification System (BDDCS) and Drug Interactions Leslie Z. Benet, PhD Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine University
More informationDrug disposition classification systems: A comparative review of BDDCS, ECCS and ECCCS
Novartis Drug disposition classification systems: A comparative review of BDDCS, ECCS and ECCCS Birk Poller, Gian Camenisch - Novartis SOLVO - Meet The Experts Transporter Conference April 26, 2018 Drug
More informationEffects of Uptake and Efflux Transporter Inhibition on Erythromycin Breath Test Results
nature publishing group Effects of Uptake and Efflux Transporter Inhibition on Erythromycin Breath Test Results LA Frassetto 1, S Poon 2, C Tsourounis 2, C Valera 2 and LZ Benet 3 The erythromycin breath
More informationBuilding innovative drug discovery alliances. Hepatic uptake and drug disposition o in vitro and in silico approaches
Building innovative drug discovery alliances Hepatic uptake and drug disposition o in vitro and in silico approaches Dr Beth Williamson Evotec AG, 2017 Outline Importance of predicting clearance In vitro
More informationDistinguishing between the Permeability Relationships with Absorption and Metabolism To Improve BCS and BDDCS Predictions in Early Drug Discovery
This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes. pubs.acs.org/molecularpharmaceutics
More informationDMPK. APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology
DMPK APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology What I learned is a good DMPK profile have acceptable water solubility for development be completely absorbed, preferably via
More informationComparison Between the US FDA, Japan PMDA and EMA In Vitro DDI Guidance: Are we Close to Harmonization?
Comparison Between the US FDA, Japan PMDA and EMA In Vitro DDI Guidance: Are we Close to Harmonization? Brian Ogilvie, Ph.D. VP Scientific Consulting XenoTech, LLC bogilvie@xenotechllc.com 14 Jun, 2018
More informationClick to edit Master title style
A Short Course in Pharmacokinetics Chris Town Research Pharmacokinetics Outline Pharmacokinetics - Definition Ideal Pharmacokinetic Parameters of a New Drug How do we optimize PK for new compounds Why
More informationStrategy on Drug Transporter Investigation Why, How, Which & When. Jasminder Sahi
Strategy on Drug Transporter Investigation Why, How, Which & When Jasminder Sahi Intestine Drug Absorption PEPT1 OATPs MCTs AE2 Epithelial Cell MCTs MRP3 Liver Excretion via Liver Kidney MRPs OATPs N PT1
More informationThe Influence of Physicochemical Properties on ADME
The Influence of Physicochemical Properties on ADME Iain Martin Iain Martin; Physchem Forum 2 1 Physchem and ADME A quick tour of the influence of physicochemical properties on: Absorption Distribution
More informationDrug Absorption and Bioavailability
Drug Absorption and Bioavailability Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 4, 2012 Office of Clinical Research Training and Medical Education National Institutes
More informationApplied Biopharmaceutics & Pharmacokinetics Sixth Edition
Applied Biopharmaceutics & Pharmacokinetics Sixth Edition Hill Leon Shargel, PHD, RPh Applied Biopharmaceutics, LLC Raleigh, North Carolina Affiliate Associate Professor, School of Pharmacy Virginia Commonwealth
More informationStrategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population
Strategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population Nina Isoherranen Department of Pharmaceutics University of Washington Processes driving drug disposition are
More informationDevelopment of Canagliflozin: Mechanistic Absorption Modeling During Late-Stage Formulation and Process Optimization
Development of Canagliflozin: Mechanistic Absorption Modeling During Late-Stage Formulation and Process Optimization Nico Holmstock Scientist, Janssen R&D M CERSI 2017, BALTIMORE (USA) Canagliflozin An
More informationUsing Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop
Using Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop Topics to be Addressed Why AMS? AMS for mass balance studies with vismodegib AMS for absolute bioavailability
More informationVolume 1(3) May-June 2013 Page 351
ISSN: 2321-5674(Print) BIOAVAILABILITY: CRITERIA FOR APPROVING A DRUG PRODUCT FOR MARKETING Sandhya Singh 1, Faheem Ajmal Ansari 1, Shravan Paswan 2*, Rnjan Kumar Sharma 2, Alok Ranjan Gaur 3 1 Azad Institute
More informationThe ADME properties of most drugs strongly depends on the ability of the drug to pass through membranes via simple diffusion.
1 MEDCHEM 562 Kent Kunze Lecture 1 Physicochemical Properties and Drug Disposition The ADME properties of most drugs strongly depends on the ability of the drug to pass through membranes via simple diffusion.
More informationChristian Wagner (Autor) Predicting the Oral Absorption of Poorly Soluble Drugs
Christian Wagner (Autor) Predicting the Oral Absorption of Poorly Soluble Drugs https://cuvillier.de/de/shop/publications/6557 Copyright: Cuvillier Verlag, Inhaberin Annette Jentzsch-Cuvillier, Nonnenstieg
More informationEvaluation of Drug-Drug Interactions FDA Perspective
Evaluation of Drug-Drug Interactions FDA Perspective Kellie Schoolar Reynolds, Pharm.D. Deputy Director Division of Clinical Pharmacology IV Office of Clinical Pharmacology Office of Translational Sciences
More informationT Eley, Y-H Han, S-P Huang, B He, W Li, W Bedford, M Stonier, D Gardiner, K Sims, P Balimane, D Rodrigues, RJ Bertz
IN VIVO AND IN VITRO ASSESSMENT OF ASUNAPREVIR (ASV; BMS-650032) AS AN INHIBITOR AND SUBSTRATE OF ORGANIC ANION TRANSPORT POLYPEPTIDE (OATP) TRANSPORTERS IN HEALTHY VOLUNTEERS T Eley, Y-H Han, S-P Huang,
More informationDefine the terms biopharmaceutics and bioavailability.
Pharmaceutics Reading Notes Define the terms biopharmaceutics and bioavailability. Biopharmaceutics: the area of study concerning the relationship between the physical, chemical, and biological sciences
More informationBasic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics
Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Learning Outcomes Define biopharmaceutics Describe 4 processes of pharmacokinetics Describe factors that affect medication absorption Describe
More informationCytochrome P450 Drug Interaction Table Flockhart Table
Cytochrome P450 Drug Interaction Table Flockhart Table The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. CYTOCHROME P450 DRUG INTERACTION TABLE A
More informationCaveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 How to Safeguard that Metrics Reflect E/T Activity? in healthy
More informationIntroduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017
Introduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017 1 Outline Definition & Relevance of Pharmacokinetics
More informationDrug Absorption and Bioavailability
Drug Absorption and Bioavailability Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 1, 2015 Office of Clinical Research Training and Medical Education National Institutes
More informationDrug Absorption and Bioavailability
Drug Absorption and Bioavailability Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 1, 2015 Office of Clinical Research Training and Medical Education National Institutes
More informationCurrent Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Current Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 Definition Phenotyping is quantifying the in vivo activity
More informationControlling ADME through Chemical Design. Marty Mulvihill Chris Vulpe
Controlling ADME through Chemical Design Marty Mulvihill Chris Vulpe ADME Chemical Processes in ADME Wang and Skolnik, Chemistry and Biodiversity, 2009, 1887. Controlling toxicity through ADME Toward molecular
More information1 Introduction: The Why and How of Drug Bioavailability Research
j1 1 Introduction: The Why and How of Drug Bioavailability Research Han van de Waterbeemd and Bernard Testa Abbreviations ADME EMEA FDA NCE PD P-gp PK R&D Absorption, distribution, metabolism, and excretion
More informationEffect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir
Effect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir Eley T, 1 He B, 1 Huang S-P, 2 Stonier M, 1 Bedford
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationItraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential
Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential Alice Ban Ke, Ph.D. Consultant & Scientific Advisor Simcyp Limited Alice.Ke@certara.com
More informationExcipient Interactions Relevant For BCS Biowaivers Peter Langguth
Excipient Interactions Relevant For BCS Biowaivers Peter Langguth Department of Pharmaceutical Technology and Biopharmaceutics, Johannes Gutenberg University Mainz, Germany 3rd Symposium on Harmonization
More informationUSING PBPK MODELING TO SIMULATE THE DISPOSITION OF CANAGLIFLOZIN
USING PBPK MODELING TO SIMULATE THE DISPOSITION OF CANAGLIFLOZIN Christophe Tistaert PDMS Pharmaceutical Sciences Preformulation & Biopharmaceutics AAPS 2015, FLORIDA (USA) Canagliflozin An orally active
More informationHTPK: Conducting PK modeling and
HTPK: Conducting PK modeling and simulations at high speed November 5, 2018 Robert Fraczkiewicz, David Miller, Marvin Waldman, Robert D. Clark Slide 1 Session Description and Objectives HTPK lightens the
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More informationMetformin IR tablets: partial in vitro dissolution profiles differences do not preclude in vivo bioequivalence
Metformin IR tablets: partial in vitro dissolution profiles differences do not preclude in vivo bioequivalence Eva Troja Quality Control Department Profarma SH.A. Pharmaceutical Industry Tirana, Albania
More informationDRUG METABOLISM AND PHARMACOKINETICS (DMPK) Lena Gustavsson, H. Lundbeck A/S, November 2015
DRUG METABOLISM AND PHARMACOKINETICS (DMPK), H. Lundbeck A/S, LEGU@lundbeck.com November 2015 DMPK in Drug Discovery and Development Agenda Introduction Optimizing pharmacokinetic properties Absorption
More informationBasic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations
Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations Rosenbaum, Sara E. ISBN-13: 9780470569061 Table of Contents 1 Introduction to Pharmacokinetics and Pharmacodynamics.
More informationWelcome to the webinar... We will begin shortly
Welcome to the webinar... We will begin shortly Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir,
More informationPharmacokinetics in Drug Development. Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core
Pharmacokinetics in Drug Development Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core Finding new drugs: A crap shoot Clinical Development Phase
More informationBIOPHARMACEUTICS and CLINICAL PHARMACY
11 years papers covered BIOPHARMACEUTICS and CLINICAL PHARMACY IV B.Pharm II Semester, Andhra University Topics: Absorption Distribution Protein binding Metabolism Excretion Bioavailability Drug Interactions
More informationAltered GI absorption in special populations: An industry perspective
Altered GI absorption in special populations: An industry perspective Cordula Stillhart and Neil J. Parrott F. Hoffmann La Roche Ltd, Basel (CH) UNGAP WG meeting, Leuven (B) 8 March 2018 Current challenges
More informationWHY... 8/21/2013 LEARNING OUTCOMES PHARMACOKINETICS I. A Absorption. D Distribution DEFINITION ADME AND THERAPEUIC ACTION
PHARMACOKINETICS I Absorption & Distribution LEARNING OUTCOMES By the end of the lecture students will be able to.. Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/08/21) Define pharmacokinetics,
More informationCurrent and Emerging Transporter Regulatory Themes in Drug Development: Relevance to Understanding PK/PD, DDIs, and Toxicity
Current and Emerging Transporter Regulatory Themes in Drug Development: Relevance to Understanding PK/PD, DDIs, and Toxicity Maciej Zamek-Gliszczynski, Ph.D. 1940 s Probenecid & anion secretion 1950 s
More informationTransporters DDI-2018
Transporters DDI-2018 Mark S. Warren, Ph.D. June 16, 2018 Senior Director of Assay Services DDI-2018: 21 st Conference on DDIs FDA guidance documents: A 21 year history 1997 2006 2012 2017 Each year, large
More informationBIOEQUIVALENCE AND THERAPEUTIC EQUIVALENCE. Soula Kyriacos, B.Pharm, PhD Head R&D, Pharmaline November 2016
BIOEQUIVALENCE AND THERAPEUTIC EQUIVALENCE Soula Kyriacos, B.Pharm, PhD Head R&D, Pharmaline November 2016 Introduction Early 1970 s FDA regulations for submission of BA data 1984 US Congress passed the
More informationCytochrome P450 Suppression in Human Hepatocyte Cultures by Small and Large Molecules. George Zhang, Ph.D. April 18, 2012
Cytochrome P450 Suppression in Human Hepatocyte Cultures by Small and Large Molecules George Zhang, Ph.D. April 18, 2012 Presentation Overview Regulatory guidance Brief review on drug-drug (Disease) interactions
More informationPharmacokinetics and bioavailability derived from various body fluids. Saliva samples instead of plasma samples
Pharmacokinetics and bioavailability derived from various body fluids Saliva samples instead of plasma samples Willi Cawello, Schwarz BioSciences, Monheim am Rhein 1 Overview Introduction Sampling tissues/fluids
More informationPursuing the holy grail of predicting and verifying tissue drug concentrations: A proteomics and PET imaging approach
Pursuing the holy grail of predicting and verifying tissue drug concentrations: A proteomics and PET imaging approach Jashvant (Jash) Unadkat Milo Gibaldi Endowed Professor Dept. of Pharmaceutics School
More informationThe BCS: Where Do We Go from Here?
The BCS: Where Do We Go from Here? Jennifer Dressman,* James Butler, John Hempenstall, and Christos Reppas Since the Biopharmaceutics Classification System (BCS) was introduced several years ago, it has
More informationPhysiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters
Physiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters Qi Wang, Wenying Li, Ming Zheng, Timothy Eley, Frank
More informationDRUG-DRUG INTERACTIONS OF GLECAPREVIR AND PIBRENTASVIR WITH PRAVASTATIN, ROSUVASTATIN, OR DABIGATRAN ETEXILATE
DRUG-DRUG INTERACTIONS OF GLECAPREVIR AND PIBRENTASVIR WITH PRAVASTATIN, ROSUVASTATIN, OR DABIGATRAN ETEXILATE Matthew P. Kosloski, Weihan Zhao, Hong Li, Stanley Subhead Wang, Calibri Joaquin 14pt, Valdes,
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationBCS: Dissolution Testing as a Surrogate for BE Studies
BCS: Dissolution Testing as a Surrogate for BE Studies Dirk M Barends National Institute of Public Health and the Environment The Netherlands APV / IKEV Seminar on Bioavailability and Bioequivalence, Istanbul,
More informationThe extended clearance model and its use for the interpretation of hepatobiliary elimination data
ADMET & DMPK 3(1) (2015) 1-14; doi: 10.5599/admet.3.1.144 Open Access : ISSN : 1848-7718 Review http://www.pub.iapchem.org/ojs/index.php/admet/index The extended clearance model and its use for the interpretation
More informationPharmacokinetic Modeling & Simulation in Discovery and non-clinical Development
Pharmacokinetic Modeling & Simulation in Discovery and non-clinical Development Where do we stand? Disclaimer I am not a bioinformatician, mathematician or biomedical engineer. I am a simple minded pharmacist,
More informationSaliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion Classification System
Drugs R D (2015) 15:79 83 DOI 10.1007/s40268-015-0080-1 ORIGINAL RESEARCH ARTICLE Saliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion
More informationUNIVERSITY OF THE WEST INDIES, ST AUGUSTINE
UNIVERSITY OF THE WEST INDIES, ST AUGUSTINE FACULTY OF MEDICAL SCIENCES SCHOOL OF PHARMACY BACHELOR OF SCIENCE IN PHARMACY DEGREE COURSE SYLLABUS COURSE TITLE: COURSE CODE: BIOPHARMACEUTICS, NEW DRUG DELIVERY
More informationQuantitative Evaluation of the Effect of P-Glycoprotein on Oral Drug Absorption
Quantitative Evaluation of the Effect of P-Glycoprotein on Oral Drug Absorption -Assessment of Drug Permeability to Rat Small Intestine- College of Pharmacy, Setsunan University, Osaka, Japan Yoshiyuki
More informationBiopharmaceutics Classification System: Defining a Permeability Class
Biopharmaceutics Classification System: Defining a Permeability Class Blair Miezeiewski, M.S. Senior Scientist, In Vitro Permeability Lab Definition of Bioequivalence The United States Food and Drug Administration
More informationOsnove farmakokinetike. Aleš Mrhar. Prirejeno po. A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne,
Osnove farmakokinetike Aleš Mrhar Prirejeno po A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne, College of Pharmacy, University of Oklahoma Pharmacokinetics/Pharmacodynamics Pharmacodynamics
More informationIPAC-RS/UF Orlando Inhalation Conference March 20, S.T. Horhota 1, C.B. Verkleij 2, P.J.G. Cornelissen 2, L. Bour 3, A. Sharma 3, M.
IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Case Study: Pharmacokinetics and Pharmacodynamics of Tiotropium and Salmeterol Following Parallel Administration in COPD Patients Using Different
More informationApplication and Experience in the EU of the BCS Concept in the review of new generics & variations
Application and Experience in the EU of the BCS Concept in the review of new generics & variations Dirk M Barends National Institute of Public Health and the Environment The Netherlands APV / IKEV Seminar
More informationStimulate your kinetic understanding Permeability Binding Metabolism Transporters
Stimulate your kinetic understanding Permeability Binding Metabolism Transporters www.simulations-plus.com +1-661-723-7723 What is MembranePlus? MembranePlus is an advanced, yet easy-to-use, modeling and
More informationPHARMACOLOGY-1 PHL-313. Ali Alhoshani Office: 2B 84
PHARMACOLOGY-1 PHL-313 Ali Alhoshani ahoshani@ksu.edu.sa http://fac.ksu.edu.sa/ahoshani Office: 2B 84 General rules Reference: General rules Email [PHL313-1 st Semester 38-39] Student ID- Question Example
More informationDetermination of bioavailability
Pharmaceutics 2 Bioavailability Bioavailability is the rate and extent to which an administered drug reaches the systemic circulation. For example, if 100 mg of a drug is administered orally and 70 mg
More informationRISK FACTORS AND DRUG TO STATIN-INDUCED MYOPATHY
RISK FACTORS AND DRUG INTERACTION PREDISPOSING TO STATIN-INDUCED MYOPATHY Assist. Prof. Dr. Verawan Uchaipichat Clinical Pharmacy Department Khon Kaen University Advanced Pharmacotherapy 2012 Updated d
More informationBiopharmaceutics. Tips Worth Tweeting. Contributor: Sandra Earle
Biopharmaceutics C H A P T E R 2 Contributor: Sandra Earle The physiochemical properties of drugs determine how they will move and interact with the body. By understanding a few principles, predictions
More informationPractical Application of PBPK in Neonates and Infants, Including Case Studies
Practical Application of PBPK in Neonates and Infants, Including Case Studies Presented at the conference : Innovative Approaches to Pediatric Drug Development and Pediatric Medical Countermeasures: A
More informationWe will begin momentarily at 2pm ET. Slides available now! Recordings will be available to ACS members after one week.
We will begin momentarily at 2pm ET Slides available now! Recordings will be available to ACS members after one week. www.acs.org/acswebinars Contact ACS Webinars at acswebinars@acs.org 1 Have Questions?
More informationUse of PBPK in simulating drug concentrations in pediatric populations: Case studies of Midazolam and Gabapentin
Use of PBPK in simulating drug concentrations in pediatric populations: Case studies of Midazolam and Gabapentin WORKSHOP ON MODELLING IN PAEDIATRIC MEDICINES April 2008 Viera Lukacova, Ph.D. Walter Woltosz,
More informationPK-UK Challenges and benefits of using PBPK to evaluate an IVIVC for drugs with nonideal solubility and/or permeability. Bath, November 2014
PK-UK 2014 Challenges and benefits of using PBPK to evaluate an IVIVC for drugs with nonideal solubility and/or permeability Bath, November 2014 Prof. Dr. Jennifer Dressman Dressman Bath 2014 Why IVIVC
More informationMODELING MECHANISM BASED INACTIVATION USING PBPK JAN WAHLSTROM DIRECTOR, PRECLINICAL
MODELING MECHANISM BASED INACTIVATION USING PBPK JAN WAHLSTROM DIRECTOR, PRECLINICAL ABSTRACT Quantitative prediction of the magnitude of drug-drug interactions (DDI) is critical to underwriting patient
More informationPharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne
Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage
More informationEMA/EGA. Session 1: orally administered Modified Release Products European Regulatory Requirements London 30 April 2015 Dr.
EMA/EGA Session 1: orally administered Modified Release Products European Regulatory Requirements London 30 April 2015 Dr. Henrike Potthast Disclaimer The presentation reflects the personal opinion of
More informationApplication of PBPK Modeling and Simulations in Drug Development
Application of PBPK Modeling and Simulations in Drug Development Ping Zhao Division of Pharmacometrics Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research
More informationMetformin: Mechanistic Absorption Modeling and IVIVC Development
Metformin: Mechanistic Absorption Modeling and IVIVC Development Maziar Kakhi *, Ph.D. FDA Silver Spring, MD 20993 Maziar.kakhi@fda.hhs.gov Viera Lukacova, Ph.D. Simulations Plus Lancaster, CA 93534 viera@simulations-plus.com
More informationFDA s Clinical Drug Interaction Studies Guidance (2017 Draft Guidance)
FDA s Clinical Drug Interaction Studies Guidance (2017 Draft Guidance) Kellie S. Reynolds, Pharm.D. Deputy Director, Division of Clinical Pharmacology IV Office of Clinical Pharmacology (OCP) Office of
More informationEffect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs
Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs James E. Polli jpolli@rx.umaryland.edu April 26, 2016 Topics BCS Class 3 excipient study
More informationAug 28 th, 2017 Pierre Daublain
Analyzing the Potential Root Causes of Variability of Pharmacokinetics in Preclinical Species to Inform Derisking Strategies in Discovery and Early Development Aug 28 th, 2017 Pierre Daublain Outline Problem
More informationA novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of simeprevir in healthy volunteers
A novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of simeprevir in healthy volunteers Sivi Ouwerkerk-Mahadevan, 1 Jan Snoeys, 1 Alex Simion,
More informationInterchangeable Drug Products - Additional Criteria
Interchangeable Drug Products - Additional Criteria Principle: Decisions respecting interchangeability and drug lists remain in the domain of the institution responsible for the costs of the product which
More informationRenal Function. 1. Glomerular filtration 2. Active tubular secretion 3. Passive tubular reabsorption 4. Excretion
59-291 Section 1, Lecture 5 Drug Excretion -most drugs are excreted in urine either as unchanged or drug metabolites Renal Function 1. Glomerular filtration 2. Active tubular secretion 3. Passive tubular
More informationComplexities of Hepatic Drug Transport: How Do We Sort It All Out?
Complexities of Hepatic Drug Transport: How Do We Sort It All Out? Keith A. Hoffmaster Pfizer Research Technology Center Cambridge, MA NEDMDG 2005 Summer Symposium 06.08.2005 The Challenge Intestinal uptake
More informationViera Lukacova Director, Simulation Sciences
Use of In Silico Mechanistic Models to Support Interspecies Extrapolation of Oral Bioavailability and Formulation Optimization: Model Example Using GastroPlus Viera Lukacova Director, Simulation Sciences
More informationTracer studies in GSK for Discovery and Development
Tracer studies in GSK for Discovery and Development 3 rd June 2010...a ripple or a wavefront? Graeme Young, DMPK, GlaxoSmithKline R&D, Ware, UK Outline Historical use of AMS at GSK variety of ADME studies;
More information1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?
Page 1 PHAR 750: Biopharmaceutics/Pharmacokinetics October 23, 2009 - Form 1 Name: Total 100 points Please choose the BEST answer of those provided. For numerical answers, choose none of the above if your
More informationDrug Penetration to Sanctuary Sites Oral vs. IV Administration
Drug Penetration to Sanctuary Sites Oral vs. IV Administration Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious Diseases University
More informationPharmacokinetics of Rifampicin in African Children Evaluation of the new WHO dosing guidelines
Pharmacokinetics of Rifampicin in African Children Evaluation of the new WHO dosing guidelines Paolo Denti, Carmen Gonzalez-Martinez, Jana Winckler, Adrie Bekker, Heather Zar, Gerry Davies, Annelies van
More informationSuitability of Digoxin as a P Glycoprotein Probe: Implications of Other Transporters on Sensitivity and Specificity
Review Suitability of Digoxin as a P Glycoprotein Probe: Implications of Other Transporters on Sensitivity and Specificity The Journal of Clinical Pharmacology XX(XX) 1 11 2013, The American College of
More informationPharmacokinetics of strong opioids. Susan Addie Specialist palliative care pharmacist
Pharmacokinetics of strong opioids Susan Addie Specialist palliative care pharmacist What is the difference between pharmacokinetics and pharmacodynamics? Definitions Pharmacokinetics = what the body does
More informationGeneric Drug Approval Process
1 Generic Drug Approval Process Sharon Ricciardo Katherine P. Weld. M.S., Ph.D. AAVPT Veterinary Drug Regulatory Life Cycle Course March 2, 2011 Overview Background Approval Process Bioequivalence Special
More informationBasic Concepts in Pharmacokinetics. Leon Aarons Manchester Pharmacy School University of Manchester
Basic Concepts in Pharmacokinetics Leon Aarons Manchester Pharmacy School University of Manchester Objectives 1. Define pharmacokinetics 2. Describe absorption 3. Describe distribution 4. Describe elimination
More informationYvonne Y. Lau, Hideaki Okochi, Yong Huang, and Leslie Z. Benet
0090-9556/06/3407-1175 1181$20.00 DRUG METABOLISM AND DISPOSITION Vol. 34, No. 7 Copyright 2006 by The American Society for Pharmacology and Experimental Therapeutics 9076/3121398 DMD 34:1175 1181, 2006
More informationOpen Questions on Bioequivalence
Master Universitario di II Livello Ricerca e Sviluppo Pre-Clinico e Clinico del Farmaco Modulo 4 Sviluppo Clinico dei Farmaci Open Questions on Bioequivalence Docente: Prof. Antonio MARZO e-mail: antoniop.marzo@libero.it
More informationMonica Edholm Medica Medic l a Pr oducts Agency
EMA EFPIA workshop Break-out session no. 2 Case Study Title: M&S for dose adjustment in impaired patients M&S for dose adjustment in renally Monica Edholm MedicalProducts Agency Disclaimer: The views expressed
More information